Gordmans Stores, Inc. (NASDAQ:GMAN) reported a Q1 loss of $0.04 per share, or $0.01, ex-items, $0.01 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $143 million versus the consensus estimate of $141.9 million. Gordmans Stores, Inc. (NASDAQ:GMAN) stock opened today at $4.35 and is currently trading at $4.48. The stock showed a positive weekly performance of 7.54%.
Retrophin Inc. (NASDAQ:RTRX) today announced the hiring of Alvin Shih M.D. as Executive Vice President of Research and Development effective June 2 2014. In this role he will oversee all medical clinical and research functions. Dr. Shih joins Retrophin from Pfizer Inc. (NYSE:PFE) where he was Chief Operating Officer of the Rare Disease Research Unit. Retrophin Inc. (NASDAQ:RTRX) stock opened at $13.38, in current trading session and currently is at $13.40, by losing -3.80%. The 52 week range of $4.50 – $24.25. Company’s market capitalization is 341.50 million.
HomeAway Inc. (NASDAQ:AWAY) shares are falling, down -2.88%, in pre-market trading on Thursday following a downgrade to “neutral” from “overweight” by analysts at JPMorgan (JPM). HomeAway, Inc. (NASDAQ:AWAY) stock is currently trading at $29.80. The EPS of the stock is 0.18. Company’s market capitalization is 2.79 billion.
NewLead Holdings Limited (NASDAQ:NEWL) seeing added pressure following Frontline’s quarterly results on Tuesday. Shares of Newlead moved to $4.40, a rather sharp move for the month of May. NewLead Holdings Ltd (NASDAQ:NEWL) stock opened the session at $2.35, and now is at $2.30. The 52 week range of the NewLead Holdings Ltd (NASDAQ:NEWL) stock remained $0.38 – $8,235.02 and the day range was $2.30 – $2.64.
Celgene Corporation (NASDAQ:CELG) was downgraded by research analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a report released on Thursday, TheFlyOnTheWall.com reports. They currently have a $170.00 target price on the stock, down from their previous target price of $180.00. JPMorgan Chase & Co.’s price target suggests a potential upside of 10.17% from the company’s current price. Celgene Corporation (NASDAQ:CELG) stock opened today at $152.00 and is currently trading at $153.00. The stock showed a positive weekly performance of 4.50%.